A. Company Profile

GlaxoSmithKline (NYSE:GSK) is one of the world's leading pharmaceutical companies. The company's product portfolio includes innovative treatments across a wide range of therapeutic areas. There are extensive discovery and development programs in the field of oncology at GlaxoSmithKline

B. Products

Product Pipelines

Product

Indication

Clinical Status

572016

Bladder, breast, gastric, head and neck, and lung cancers

Phase III

BEXXAR

Non-Hodgkin's lymphoma

Market

Melanoma

Phase III

Colorectal cancer

Phase II

Lymphoma and pancreatic cancer

Phase I

Cervarix

Cervical cancer

Phase III

Elacridar

Various tumors

Phase I

Ethynylcytidine

Various tumors

Phase II

Hycamtin

Small cell lung cancer (2^nd line)

Market

Non-small cell lung cancer (2^nd line), ovarian cancer (1^st line), small cell lung cancer (1^st line), and small cell lung cancer (2^nd line) - oral formulation

Phase III

Lapatinib

Breast cancer

Phase III

Navelbine

Breast and non small

cell lung cancers

Phase III

Nelarabine

Acute lymphoblastic leukaemia and lymphomas

Phase III

1. 572016

572016 is an ErbB-1 (EGFR) and ErbB-2 (HER2/NEU) dual kinase inhibitors. These two receptors have been implicated in the growth of various tumor types, and often are associated with a poor prognosis.

2. Bexxar

The Bexxar therapeutic regimen (Tositumomab and Iodine I 131 Tositumomab) is approved by the FDA for the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy.

3. Elacridar

Elacridar (GF120918), oral bioenhancer, is in the latest generation of multi-drug resistance-interacting compounds that specifically target the membrane-bound P-glycoprotein efflux pump.

4. Ethynylcytidine

Ethynylcytidine is a selective RNA polymerase inhibitor.

5. Hycamtin

Hycamtin (Topetecan) is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I inhibitory activity.

6. Lapatinib

Laptinib is a blocker of tumor growth receptor and tumor-promoting protein.

7. Navelbine

Navelbine, a vinca alkaloid, is a microtubule inhibitor. It interferes with the growth of cancer cells and slows their growth and spread in the body.

8. Nelarabine,

Nelarabine is a novel water soluble prodrug of ara-G with T- cell selectivity. It is a nucleoside analogue that is rapidly converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxity.